BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23564767)

  • 1. PTEN regulates sensitivity of melanoma cells to RO4929097, the γ-secretase inhibitor.
    Nair JS; Sheikh T; Ho AL; Schwartz GK
    Anticancer Res; 2013 Apr; 33(4):1307-16. PubMed ID: 23564767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
    Hales EC; Taub JW; Matherly LH
    Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma.
    Huynh C; Poliseno L; Segura MF; Medicherla R; Haimovic A; Menendez S; Shang S; Pavlick A; Shao Y; Darvishian F; Boylan JF; Osman I; Hernando E
    PLoS One; 2011; 6(9):e25264. PubMed ID: 21980408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cervical Cancer Cell Growth, Drug Resistance, and Epithelial-Mesenchymal Transition Are Suppressed by y-Secretase Inhibitor RO4929097.
    Wang L; Dai G; Yang J; Wu W; Zhang W
    Med Sci Monit; 2018 Jun; 24():4046-4053. PubMed ID: 29899322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
    Lee SM; Moon J; Redman BG; Chidiac T; Flaherty LE; Zha Y; Othus M; Ribas A; Sondak VK; Gajewski TF; Margolin KA
    Cancer; 2015 Feb; 121(3):432-440. PubMed ID: 25250858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the NOTCH pathway using γ-secretase inhibitor RO4929097 has limited antitumor activity in established glial tumors.
    Dantas-Barbosa C; Bergthold G; Daudigeos-Dubus E; Blockus H; Boylan JF; Ferreira C; Puget S; Abely M; Vassal G; Grill J; Geoerger B
    Anticancer Drugs; 2015 Mar; 26(3):272-83. PubMed ID: 25486598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.
    Gopal YN; Deng W; Woodman SE; Komurov K; Ram P; Smith PD; Davies MA
    Cancer Res; 2010 Nov; 70(21):8736-47. PubMed ID: 20959481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells.
    Hales EC; Orr SM; Larson Gedman A; Taub JW; Matherly LH
    J Biol Chem; 2013 Aug; 288(31):22836-48. PubMed ID: 23788636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gamma secretase inhibitor enhances sensitivity to doxorubicin in MDA-MB-231 cells.
    Li ZL; Chen C; Yang Y; Wang C; Yang T; Yang X; Liu SC
    Int J Clin Exp Pathol; 2015; 8(5):4378-87. PubMed ID: 26191129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
    Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
    Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation.
    Vo K; Amarasinghe B; Washington K; Gonzalez A; Berlin J; Dang TP
    Mol Cancer; 2011 Nov; 10():138. PubMed ID: 22074495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Essential role of Notch signaling in apoptosis of human pancreatic tumoral cells mediated by exosomal nanoparticles.
    Ristorcelli E; Beraud E; Mathieu S; Lombardo D; Verine A
    Int J Cancer; 2009 Sep; 125(5):1016-26. PubMed ID: 19405120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.
    Zhu G; Yi X; Haferkamp S; Hesbacher S; Li C; Goebeler M; Gao T; Houben R; Schrama D
    Cancer Lett; 2016 Jun; 376(1):43-52. PubMed ID: 27000992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties.
    Luistro L; He W; Smith M; Packman K; Vilenchik M; Carvajal D; Roberts J; Cai J; Berkofsky-Fessler W; Hilton H; Linn M; Flohr A; Jakob-Røtne R; Jacobsen H; Glenn K; Heimbrook D; Boylan JF
    Cancer Res; 2009 Oct; 69(19):7672-80. PubMed ID: 19773430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097.
    He W; Luistro L; Carvajal D; Smith M; Nevins T; Yin X; Cai J; Higgins B; Kolinsky K; Rizzo C; Packman K; Heimbrook D; Boylan JF
    Mol Oncol; 2011 Jun; 5(3):292-301. PubMed ID: 21315665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.
    Fofaria NM; Frederick DT; Sullivan RJ; Flaherty KT; Srivastava SK
    Oncotarget; 2015 Dec; 6(38):40535-56. PubMed ID: 26497853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells.
    Debeb BG; Cohen EN; Boley K; Freiter EM; Li L; Robertson FM; Reuben JM; Cristofanilli M; Buchholz TA; Woodward WA
    Breast Cancer Res Treat; 2012 Jul; 134(2):495-510. PubMed ID: 22547109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Notch signaling by γ-secretase inhibitor I enhances the cytotoxic effect of 5-FU in gastric cancer.
    Lee HW; Kim SJ; Choi IJ; Song J; Chun KH
    Clin Exp Metastasis; 2015 Aug; 32(6):593-603. PubMed ID: 26134677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling.
    Kolb EA; Gorlick R; Keir ST; Maris JM; Lock R; Carol H; Kurmasheva RT; Reynolds CP; Kang MH; Wu J; Houghton PJ; Smith MA
    Pediatr Blood Cancer; 2012 May; 58(5):815-8. PubMed ID: 22052798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy of RY10-4 with the γ-secretase inhibitor DAPT shows promise in treating HER2-amplified breast cancer.
    Su F; Zhu S; Ruan J; Muftuoglu Y; Zhang L; Yuan Q
    Oncotarget; 2016 Jan; 7(4):4142-54. PubMed ID: 26716652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.